iSpecimen (ISPC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Oct, 2026Executive summary
Virtual annual meeting set for Dec. 30, 2026; Nov. 2, 2026 record date, with four proposals and unanimous Board recommendations in favor of each.
Stockholders are asked to elect a director, ratify Bush & Associates CPA LLC, approve conversion from Delaware to Nevada, and authorize adjournment if needed for votes or quorum.
Nasdaq granted an extension to Nov. 25, 2026 to evidence compliance with its $2.5 million stockholders’ equity requirement; equity was $1,736,380 at June 30, 2026, with delisting possible if compliance is not demonstrated.
Voting matters and shareholder proposals
Avtar Dhaliwal is the sole Class II nominee for a three-year term ending at the 2029 annual meeting; election requires a majority of votes cast.
Auditor ratification and adjournment each require a majority of shares present and entitled to vote; reincorporation requires a majority of all outstanding shares entitled to vote.
Proposals 1 and 3 are non-routine, so brokers cannot vote uninstructed shares; proposals 2 and 4 are routine and permit broker discretion.
Proposals for inclusion in 2027 proxy materials are due by July 23, 2027; other nominations and proposals generally require notice between Sept. 1 and Oct. 1, 2027, subject to meeting-date conditions.
Board of directors and corporate governance
Three-member classified Board: Tommy Lee, Class I, through 2028; Dhaliwal, Class II, up for election; Anthony Lau, Class III, through 2027.
Dhaliwal, Lau and Lee were determined independent under Nasdaq rules; Lau chairs Audit and Compensation, while Dhaliwal chairs Nominating and Corporate Governance.
Board and committee attendance was at least 75% for each director during their service in FY2025; Section 16 insiders were reported compliant with timely filing requirements for 2025.
A written business conduct and ethics code applies to directors, officers and employees, with website disclosure of legally or Nasdaq-required amendments and waivers.
Latest events from iSpecimen
- Stockholders approved a reverse split proposal with a board-set ratio from 1-for-10 to 1-for-100.ISPC
EGM 2026 - Reverse split vote resumes Oct. 30 under a FOR-versus-AGAINST standard.ISPC
Proxy filing - Four proposals cleared preliminary voting; the reverse-split vote stays open through Oct. 30.ISPC
AGM 2026 - Reverse-split vote adjourned to October 30 under a votes-for-must-exceed-against standard.ISPC
Proxy filing - Special Meeting seeks approval for stock issuances, reverse split, and AI asset acquisition.ISPC
Proxy filing - Stockholders will vote on share issuances, a reverse split, and an AI asset acquisition.ISPC
Proxy filing - Revenue fell 83% and net loss widened, raising substantial doubt about going concern status.ISPC
Q2 2026 - Raising up to $5M via best-efforts offering to fund operations, marketing, and platform growth.ISPC
Registration filing - Biospecimen marketplace seeks up to $4M via Nasdaq offering amid ongoing losses and liquidity risks.ISPC
Registration filing